Entrada Therapeutics, Inc.
About Entrada Therapeutics, Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $25.4M
- Net income
- -$143.8M
- Total assets
- $377.4M
- Market cap
- $247.3M
- Operating margin
- -621.1%
- Net margin
- -565.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $25.4M
- Operating expenses
- $183.3M
- Operating income
- -$157.9M
- Income tax
- $924.0K
- Net income
- -$143.8M
- EPS (basic)
- $-3.47
- EPS (diluted)
- $-3.47
Balance sheet
- Total assets
- $377.4M
- Current assets
- $306.3M
- Total liabilities
- $71.2M
- Current liabilities
- $24.5M
- Shareholders’ equity
- $306.1M
Cash flow
- Operating cash flow
- -$128.5M
- Investing cash flow
- $116.8M
- Financing cash flow
- $887.0K
- Net cash flow
- -$10.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $247.3M
- EPS (diluted)
- $-3.47
- Shares outstanding
- 39.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $143.8M in FY2025.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Entrada Therapeutics, Inc..
Write a review
News about Entrada Therapeutics, Inc.
News & sentiment via Polygon.io
